구분

 2차년도 (2024년)

1차년도 (2023년)

합계 

 비고

 SCI급 논문 (건)

4

3

7

※ 상위 10% 이내 논문 성과는 상위 5% 이내 성과 포함 

전체 

13

7

20

 특허 (건)

7

6

13

※ 국내특허는 PCT 특허 포함

※ 기술이전 세부내용 비공개 

2차년도 (2024)

1. Role of UPF1-LIN28A interaction during early differentiation of pluripotent stem cells., Jung S, et al., Nat Commun. 2024 Jan 2;15(1):158. 

2. Engineering TALE-linked deaminases to facilitate precision adenine base editing in mitochondrial DNA, Cho S, et al., Cell. 2024 Jan 4;187(1):95-109.e26.

3. Applications of CRISPR technologies to the development of gene and cell therapy, Park C, et al., BMB Rep. 2024 Jan;57(1):2-11.

4. Multimodal Golden DNA Superstructures (GDSs) for Highly Efficient Photothermal Immunotherapy, Kim D, et al., ACS Nano. 2024 Jan 16;18(2):1744-1755.

5. Highly efficient genome editing via CRISPR-Cas9 ribonucleoprotein (RNP) delivery in mesenchymal stem cells, Han A R, et al., BMB Rep. 2024 Jan;57(1):60-65.

6. Programmable RNA base editing with photoactivatable CRISPR-Cas13, Yu J, et al, Nat Commun. 2024 Jan 22;15(1):673.

7. Oligonucleotide therapeutics and their chemical modification strategies for clinical applications, Kim H, et al., J Pharm Investig.  2024 Feb;54:415–433.

8. Self-healing and Thermal Responsive DNA Bioplastics for On-Demand Degradable Medical Devices, Ji Y, et al., ACS Mater Lett. 2024 Mar;6(4):1277-1287.

9. ACE mRNA (Additional Chimeric Element incorporated IVT mRNA) for Enhancing Protein Expression by Modulating Immunogenicity, Son S, et al., Adv Sci (Weinh). 2024 May;11(18):e2307541.

10. Recent advances in CRISPR-based functional genomics for the study of disease-associated genetic variants, Kim H S, et al., Exp Mol Med. 2024 Apr;56(4):861-869.

11. CRISPR base editing-mediated correction of a tau mutation rescues cognitive decline in a mouse model of tauopathy, Gee M S, et al., Transl Neurodegener. 2024 Apr 12;13(1):21.

12. Pancreatic Diseases: Genetics and Modeling Using Human Pluripotent Stem Cells, Lee Y, et al., Int J Stem Cells. 2024 Apr 26.

13. Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics, Lee Y, et al., Biomater Res. 2024 May 22;28:0017.

1차년도 (2023)

1. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics, Lee Y, et al., Exp Mol Med. 2023 Oct;55(10):2085-2096.

2. Base editing of organellar DNA with programmable deaminases, Kim JS, et al., Nat Rev Mol Cell Biol. 2024 Jan;25(1):34-45.

3. Clinical Approaches for Mitochondrial Diseases, Hong S, et al., Cells. 2023 Oct 20;12(20):2494.

4. Survivin enhances hippocampal neurogenesis and cognitive function in Alzheimer's disease mouse model, Lee Y, et al., CNS Neurosci Ther. 2024 Apr;30(4):e14509.

5. Allelic hierarchy for USH2A influences auditory and visual phenotypes in South Korean patients, Nam D W, et al., Sci Rep. 2023 Nov 19;13(1):20239.

6. Precise base editing without unintended indels in human cells and mouse primary myoblasts, Yoon DE, et al., Exp Mol Med. 2023 Dec;55(12):2586-2595.

7. Artificial intelligence-driven new drug discovery targeting serine/threonine kinase 33 for cancer treatment, Tran N L, et al., Cancer Cell Int. 2023 Dec 12;23(1):321.

2차년도 (2024)

1. 세포외 염기교정 능력시험법 (출원일 2024.01.17)

2. XXX 포함하는 XXX 및 이의 용도 (출원일 2024.03.18)

3. 신규 CRISPR/Cas12a 조성물의 유전자 편집용도 (출원일 2024.03.22)

4. 신규 CRISPR/Cas12a 조성물의 유전자 편집용도(분할출원) (출원일 2024.03.24)

5. XXX 조성물 및 이의 용도 (출원일 2024.04.02)

6. XXX를 도입한 XXX 및 이의 제조 방법 (출원일 2024.05.22)

7. 닉카제를 포함하는 신규한 염기 에디터 (출원일 2024.06.13)

1차년도 (2023)

1. 신규 CRISPR/Cas12a 조성물의 유전자 편집용도 (출원일 2023.09.20)

2. XXX 포함한 생분해성 이온화지질 및 이를 이용한 핵산 약물 전달용 지질 나노입자 (출원일 2023.09.27)

3. XXX 포함한 생분해성 지질 나노입자개발 및 이를 이용한 핵산 약물 전달 (출원일 2023.09.27)

4. 신규한 키메릭 항원 수용체 (출원일 2023.11.29)

5. 다중 단백질의 발현을 위한 신규 핵산 구조체 (출원일 2023.12.04)

6. 레베르 유전성 시신경병증의 미토콘드리아 염기 변이 교정 시스템 (출원일 2023.12.28)